🔗 Share this article

Government ministers and leading parliamentarians have raised concerns that the United Kingdom's recent agreements with Washington are "fundamentally unstable." This follows revelations that a recently announced deal on medicines, which commits to zero tariffs in exchange for the NHS paying more, lacks any detailed agreement beyond broad headline terms outlined by government press releases.

Lacking Legal Footing

The US-UK pharmaceuticals agreement, hailed as a "significant" achievement, is still an "agreement in principle" without detailed provisions. Critics have noted that the public statements from the UK and US governments describe the deal in markedly contrasting terms. The British version celebrates securing "duty-free access" as a singular success, while the American announcement concentrates on the agreement for the NHS to pay significantly more for new medications.

"We face a genuine possibility that the UK government has made commitments to increase medicine costs in return for little more than a pledge from President Trump," commented David Henig, a trade policy analyst. "We know he has form for not honouring his word."

A Pattern of Unreliability

Concerns have been heightened by Washington's recent decision to suspend the high-value digital accord, which was previously described as "a generational step-change" in the bilateral relationship. The US claimed a lack of progress from the UK on reducing other tariffs as the reason for the pause.

In a separate development, concessions promised for British farmers as part of an May trade agreement have not been formally approved by the US, despite a fast-approaching January deadline. "It is our belief that the US has failed to approve the reciprocal tariff rate quota," said Tom Bradshaw of the National Farmers' Union.

Uncertainty Among Officials

In confidential discussions, ministers have voiced worries that the government's agreements with the US are lacking substance. One minister reportedly said the series of agreements as "built on sand," while another described the situation as the "current reality" in the transatlantic relationship, marked by "increased uncertainty and instability."

Layla Moran, a senior MP on the health committee, stated: "Perhaps most shocking than the US approach is the UK government's optimistic assumption that his administration is a reliable partner. The NHS is of vital importance."

A Mixed Picture of Success and Setback

Ministry sources have sought to reduce the possibility of the US backing out of the pharmaceuticals deal. One source suggested the US pharmaceutical industry itself had been advocating for the agreement, wanting clarity on imports and pricing, making it more concrete than the paused tech deal.

Officials admit that unpredictability is inherent in dealing with the Trump administration. However, they argue that the UK has obtained tangible results for businesses, such as preferential tariff rates compared to other nations. "The fact we have 25% steel tariffs, which is lower than the rate for the rest of the world, is a solid gain," one official said.

Yet, problems have surfaced in carrying out the May tariff agreement. Promised quotas on beef exports have not materialized, and the pledge to "eliminate duties on UK metals" has is still pending, with tariffs staying at 25%.

As negotiations continue, the two sides have agreed to resume talks on the suspended digital agreement in January, following what were described as "very positive" meetings between UK and US officials in Washington.